Insider Trading Activity For bluebird bio, Inc. (NASDAQ:BLUE)
Jeffrey T Walsh , Insider of bluebird bio, Inc. (NASDAQ:BLUE) reportedly Sold 1,250 shares of the company’s stock at an average price of 95.41 for a total transaction amount of $119,262.50 SEC Form
Insider Trading History For bluebird bio, Inc. (NASDAQ:BLUE)
Analyst Ratings For bluebird bio, Inc. (NASDAQ:BLUE)
These are 2 Sell Ratings, 5 Hold Ratings, 11 Buy Ratings .
The current consensus rating for bluebird bio, Inc. (NASDAQ:BLUE) is Buy (Score: 2.50) with a consensus target price of $99.58 , a potential (3.08% upside)
Analyst Ratings History For bluebird bio, Inc. (NASDAQ:BLUE)
- On 11/5/2015 Oppenheimer Holdings, Inc. Reiterated Rating Outperform with a price target of $162.00
- On 5/5/2016 Wells Fargo & Company Reiterated Rating Buy
- On 10/14/2016 SunTrust Banks, Inc. Reiterated Rating Buy
- On 10/15/2016 Goldman Sachs Group, Inc. (The) Reiterated Rating Buy with a price target of $135.00
- On 11/30/2016 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $95.00
- On 12/1/2016 Leerink Swann Boost Price Target of rating Outperform with a price target of $80.00 to $85.00
- On 12/7/2016 J P Morgan Chase & Co Reiterated Rating Buy with a price target of $120.00
Recent Trading Activity for bluebird bio, Inc. (NASDAQ:BLUE)
Shares of bluebird bio, Inc. closed the previous trading session at 96.60 up +2.65 2.82% with 427,482 shares trading hands.